抗凝与抗血小板治疗患者颈动脉支架置入术后支架内狭窄或闭塞的比较
单中心回顾性队列研究纳入327例颈动脉支架置入患者,比较抗凝组(53例)与抗血小板组(274例)的支架内狭窄。短期狭窄率无差异,中期抗凝组狭窄率更高(21.6% vs 7.4%,P=.01;调整OR 3.29,95%CI 1.16-9.39),但敏感性分析未显示显著关联(OR 1.29,95%CI 0.54-3.07,P=.56)。
要点
- 抗凝患者中期支架内狭窄率高于抗血小板患者,但敏感性分析未证实。
- 中期症状性狭窄仅见于抗凝组,且均为DOAC使用者。
- 需前瞻性研究指导抗凝患者CAS术后抗血栓策略。
核心结论
- 主要分析显示抗凝药尤其是DOAC与中期(症状性)支架内狭窄增加相关,但敏感性分析中关联减弱。
研究设计与样本
- 单中心回顾性队列研究,纳入2005年5月至2024年9月接受CAS的重度颈动脉狭窄患者327例,抗凝组53例(16.2%),抗血小板组274例(83.8%)。
主要发现
- 短期(30天至8周)支架内狭窄率两组无差异(2.1% vs 2.8%,P=1.00)。
- 中期(1年)支架内狭窄率抗凝组高于抗血小板组(21.6% vs 7.4%,P=.01;调整OR 3.29,95%CI 1.16-9.39)。
- 中期症状性狭窄抗凝组多于抗血小板组(10.5% vs 1.0%,P=.01),全部发生于DOAC使用者,其中75%同时接受单抗血小板治疗。
- 敏感性分析(多重插补)未显示显著关联(OR 1.29,95%CI 0.54-3.07,P=.56)。
- 30天血栓栓塞与出血复合终点、再干预及其他手术相关不良事件两组无显著差异。
临床怎么用
- 对接受抗凝治疗的患者行CAS后,应加强中期支架内狭窄的影像学监测。
局限性
- 单中心回顾性设计,敏感性分析后关联不显著,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rise in anticoagulant use increases the likelihood that patients undergoing carotid artery stenting (CAS) are on anticoagulants. This complicates postprocedural antithrombotic management, as dual antiplatelet therapy is standard to reduce stent-related complications. To mitigate bleeding risks, patients on anticoagulants often briefly receive a single antiplatelet agent instead. Based on clinical practice, we hypothesized this regimen may increase in-stent stenosis, potentially raising the risk of recurrent ipsilateral transient ischemic attack or ischemic stroke. DESIGN: Single-center, retrospective cohort study at a tertiary referral center. METHODS: Patients with significant carotid artery stenosis treated with CAS (May 2005 to September 2024) were categorized into the anticoagulant (with or without antiplatelet therapy) or antiplatelet group (mono therapy or dual therapy). Primary outcome was in-stent stenosis at short-term (30 days to 8 weeks) and mid-term (1 year) follow-ups. Secondary outcomes included 30-day composite of thromboembolic and bleeding complications, reintervention, and other procedure-related adverse events. For the sensitivity analysis, multiple imputation was performed to address missing data. RESULTS: Among 327 patients, 274 (83.8%) received antiplatelets and 53 (16.2%) anticoagulants. In-stent stenosis rates did not differ at short term (2.1% vs 2.8%, P = 1.00) but were higher in the anticoagulant group at mid-term (21.6% vs 7.4%, P = .01; adjusted odds ratio [OR] 3.29, 95% confidence interval [CI] 1.16-9.39), with more symptomatic cases (10.5% vs 1.0%, P = .01). All occurred in direct oral anticoagulant (DOAC) users, 75% also on single antiplatelet therapy. However, sensitivity analysis yielded a non-significant association (OR 1.29, 95% CI 0.54-3.07, P = .56). Secondary outcomes showed no significant differences. CONCLUSION: Anticoagulant use, specifically DOACs, appears associated with increased mid-term (symptomatic) in-stent stenosis in the primary analysis. However, this association was attenuated in the sensitivity analysis. Prospective studies are warranted to guide post-CAS antithrombotic therapy in anticoagulated patients.Clinical ImpactAs the number of patients undergoing carotid artery stenting while receiving oral anticoagulation continues to rise, clinicians face uncertainty regarding optimal post-procedural antithrombotic therapy. This study identifies a potential association between anticoagulant use, particularly direct oral anticoagulants, and increased mid-term carotid in-stent stenosis. Confirmation in prospective studies is required. The innovation of this study lies in addressing an important evidence gap in carotid intervention practice, providing the first comparison of in-stent stenosis outcomes between anticoagulant- and antiplatelet-treated patients.
引用
- Kök M, Bokkers RPH, Mazuri A, et al. In-Stent Stenosis or Occlusion After Carotid Artery Stenting in Patients Treated With Anticoagulants vs Antiplatelet Therapy. J Endovasc Ther. 2026. PMID: 42366638. doi:10.1177/15266028261456460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。